Best Growth Stocks to Buy for September 14th

Zacks highlighted BP, National Energy Services Reunited and Centene as Zacks Rank #1 (Strong Buy) growth candidates. Current-year consensus EPS estimates increased 32.4% for BP, 6.4% for NESR and 40.9% for Centene over the past 60 days. The article is analyst-driven stock-selection commentary rather than company-specific operational news, limiting expected market impact.

Analysis

This is low-information sell-side marketing rather than a fundamental catalyst; estimate revisions are backward-looking and insufficient to underwrite a position without identifying the underlying drivers. BP's revision momentum is only investable if it reflects a sustained commodity-price or operational uplift rather than a one-quarter trading/refining reset. The relevant transmission is oil and gas prices into upstream cash flow, offset by downstream margin normalization and BP's relatively high transition-capex burden versus XOM and CVX.

NESR merits a watchlist rather than immediate action. Its Middle East/North Africa exposure can create stronger incremental pricing and utilization than North American pressure-pumping peers when regional capacity tightens, but the small-cap liquidity profile means consensus changes can be stale and the equity is vulnerable to contract concentration, receivable collection, and geopolitical disruptions. Verify backlog conversion, EBITDA margin guidance, net leverage, and days-sales-outstanding before treating the estimate change as earnings quality.

CNC's large revision is potentially more material, but managed-care earnings can move sharply on medical-loss-ratio development, risk-adjustment accruals, and Medicaid redetermination membership/mix rather than durable growth. A favorable revision without a corresponding improvement in 2026 medical-cost trend or state-rate adequacy should not command multiple expansion; the next earnings release and any Medicaid rate notices are the near-term falsifiers. QBTS has no evidenced linkage to this item and should be excluded from any thematic read-through.

Key Decisions for Investors

• No event-driven trade on the publication itself; reassess BP only after confirming whether consensus upgrades exceed changes in Brent/Henry Hub forward curves and whether management raises operating-cash-flow or buyback guidance at the next results.
• Watch BP versus XOM as a relative-value setup over 1-3 months: consider long BP/short XOM only if BP's forward EPS revisions continue to outperform by at least 10 percentage points while Brent remains above BP's budget assumptions. Exit on a material Brent decline or BP buyback/capex guidance disappointment.
• Place NESR on an earnings-alert list rather than initiate: a long is warranted only if reported backlog, utilization, and EBITDA guidance validate the revision while net leverage declines. Use modest sizing given liquidity and regional political risk; a missed receivables or margin metric would falsify the thesis.
• For CNC, wait for medical-loss-ratio and membership disclosures. Consider a 3-6 month long only if management confirms rate adequacy and maintains full-year EPS despite utilization trends; otherwise, the estimate revision is more likely to reverse than support a rerating.